Companies › TORL Biotherapeutics
5 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TORL-1-23 antibody drug conjugate (ADC) | – | Phase 2 | Epithelial Ovarian Cancer; Advanced Solid Tumor; FIGO Stage III and IV Ovarian Cancer | Nov 2026 |
| TORL-2-307-ADC antibody-drug conjugate | – | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| TORL-4-500 antibody-drug conjugate | – | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| TORL-5-700 | – | Phase 1 | Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Mar 2029 |
| TORL-3-600 antibody-drug conjugate | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05948826 | TORL-3-600 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2026 |
| NCT05103683 | TORL-1-23 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2026 |
| NCT05156866 | TORL-2-307-ADC | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2027 |
| NCT06005740 | TORL-4-500 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2027 |
| NCT06690775 | TORL-1-23 | Phase 2 | Epithelial Ovarian Cancer | Oncology | Oct 2027 |
| NCT07322094 | TORL-1-23 | Phase 1 | FIGO Stage III and IV Ovarian Cancer | Oncology | Dec 2027 |
| NCT07439653 | TORL-5-700 | Phase 1 | Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Oncology | Mar 2029 |
No annotated target.
–
Avistone Biotechnology Nanjing Sanhome Pharmaceutical Shandong Boan Biotechnology Taiho Pharmaceutical Jacobio Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.